

INVION LIMITED ISSUER CODE CHANGE TO ASX:IVX

BRISBANE, 4 SEPTEMBER 2012: Clinical-stage drug development company Invion Limited wishes to confirm that the company's name and issuer code change becomes effective on the ASX as of Wednesday 5 September 2012.

From market open on that date, the company's issuer code will be IVX (ASX:IVX).

About Invion Limited

Invion Limited (Invion) is a clinical-stage drug development company that targets inflammation. Invion exploits the patented use of *beta-2 adrenergic inverse agonism* for the development of treatments for major market opportunities in inflammatory conditions of the lungs such as asthma, chronic bronchitis and cystic fibrosis. Invion's key development asset is INV102, also known as nadolol, which been used in more than 8 million people for the treatment of high blood pressure, migraine and chest pain. Invion is now targeting INV102 for new indications.

To date, two phase II clinical trials of INV102 have been completed which have demonstrated acceptable safety as well as dose-related activity showing a reduction of airway hyper-responsiveness. Two further phase II trials are due to commence in H2 2012. The larger of these two trials, a phase II \$4.4 million study in asthma patients, is expected to be entirely funded by the US National Institutes of Health. Invion is also progressing regulatory preparations to investigate its second compound Cpn10 as a treatment for the autoimmune disease lupus. Invion has received confirmation from the US Food and Drug Administration (FDA) regarding the timing of a pre-Investigational New Drug (pre-IND) meeting to discuss the proposed development path and regulatory strategy for this compound.

FOR MORE INFORMATION CONTACT:

Corporate

Dr William Garner
Managing Director and CEO
Invion Limited
investor@invion.com.au

Investor Relations

Rebecca Wilson
Buchan Consulting
03 9866 4722
rwilson@buchanwe.com.au

Media

Tom Donovan
Buchan Consulting
(03) 9866 4722
tdonovan@buchanwe.com.au